The effects of glucagon-like peptide-l (GLP-1) antiserum on glucose tolerance and insulin secretion were examined in un-restrained, un-anesthetized rats. In antibody-treated rats the plasma glucose, immunoreactive insulin (IRI) and glucagon immunoreactivity levels were similar to those of control rats treated with normal rabbit serum (NRS) in the starved state. In control experiments, the same amount of anti-GLP-l immunoglobulins significantly reduced the insulinotropic effect of exogenous GLP-l(7-36 amide) infused at a rate of 50 ng/kg/min together with glucose (6.3 mg/kg/min). No significant difference was found in the plasma glucose or IRI levels or the respective l20-min integrated areas after an oral glucose load (l g/kg) in animals treated with GLP-l antibodies and control animals treated with NRS (IRI: 8.5il.6 nmol/l min in controls vs. 6.4.-tl.2 nmol/l min in antibodytreated rats). After an oral glucose load, the level of plasma GLP-l immunoreactivity (IR GLP-l) decreased slightly, but significantly, from the basal level of 197i ll pmol/l to a nadir of 160-i9.7 pmol/l at 90 min in control rats. The plasma glucose and IRI levels after an intraduodenal glucose load (l g/kg) did not differ significantly in the group treated with GLP-l antiserum and the control group. However, the 120-min integrated IRI response to the glucose load was significantly less in the group treated with GLP-l antiserum than in the control group (5.0il.l nmol/l min vs. l8.6i2.9 nmol/l min, P<0.005). The plasma IR GLP-l level was significantly increased after an intraduodenal glucose load from 145i l5 pmol/l in the basal state to a peak after 90 min of l9li22 pmol/l.
The main candidate for incretin, a hormonal factor in the gut that enhances nutrient disposal, has been thought to be gastric inhibitory polypeptide (GIP), which enhances glucose-stimulated insulin release in man (l, 2, 4, ll) . However, administration of GIP antibodies does not abolish the incretin effect (3), implying that other factors are involved.
Recently, glucagon-like peptide l (GLP-1), especially a smaller form of GLP-l, GLP-l(7-36 amide), was found to have a potent effect in enhancing glucose-induced insulin release at physiological concentrations in humans (7), pigs (6), and rats (8, l2). The effective concentration of GLP-l(7-36 amide) for a similar effect to GIP on glucose-stimulated insulin release was reported to be as low as one-tenth of that of GIP under the same experimental conditions (12), indicating that GLP-l(7-36 amide) has a greater insulinotropic effect than GIP. Furthermore, GLP-l(7-36 amide) is released from the gut after an oral glucose load (6). These findings suggest that this peptide may function as an incretin.
